Cash-Pay GLP-1 If BMI Is Too Low for Medicare Bridge

Before you spend a dollar: the BMI in your chart today may not be the BMI Medicare is supposed to use.

Yes, a cash-pay GLP-1 if BMI is too low for Medicare Bridge may still be possible—but check your starting BMI first. CMS uses the BMI you had when you began GLP-1 therapy, not automatically the lower BMI you have now. If your starting BMI really missed the Bridge rules, a clinician may still find that you fit an FDA-approved weight-management use. Direct medication prices currently run from $149 to $699 a month, depending on the medicine, dose, offer, and refill timing. Paying cash keeps that purchase outside Medicare. It does not guarantee a prescription.¹

Some people comparing a $349 cash price may qualify for the $50 Bridge copay after the correct starting BMI is submitted. The first job is not choosing a provider. It is finding out which rule actually applies to you.

Affiliate disclosure: Weight Loss Provider Guide may earn a commission if you use certain provider links on this page. It does not change your price or our conclusions. The cheapest path for many readers—using the Bridge or using an existing prescriber with a manufacturer-direct pharmacy—is not an affiliate route.

Last verified: August 5, 2026
CMS rules, covered Bridge products, manufacturer cash prices, and provider fees were checked against current government, manufacturer, and provider sources.

Start here: which one sounds like you?

Medicare GLP-1 Starting-BMI Path Checker

Answer only the questions needed to sort your path:

• Your current BMI
• Your BMI when you first began GLP-1 therapy
• About when therapy began
• Whether a Part D plan paid for a GLP-1 fill in 2026
• Whether you have a Part D-covered indication
• Whether you had a Bridge-listed condition when therapy began
• Whether you already have a prescriber willing to help
• Whether you prefer a pill or injection
• What monthly cost you can sustain

Do not enter your Medicare number, Social Security number, date of birth, full name, or upload medical records.

Your result will be one of four plain answers:

1. Correct and resubmit using your starting BMI
2. Use regular Part D first
3. Ask for a clinical cash-pay evaluation
4. Stop commercial routing and ask a clinician what care is appropriate

Check which BMI Medicare should use →

Is Your BMI Actually Too Low for the Medicare GLP-1 Bridge?

Maybe not. The Medicare GLP-1 Bridge uses your BMI at the time you began GLP-1 therapy, not automatically your BMI today. Five quick checks can tell you whether you need cash pay at all.

We put this section first because each check can save hundreds of dollars a month. None starts with an affiliate provider.

Check 1: Medicare uses your BMI from when you started

This is the big one, and many people have never been told.

CMS says Bridge eligibility is based on your BMI at initiation of GLP-1 therapy. The government gives its own example: a person who started in September 2024 at a BMI of 37 and later reached 34 should be assessed using the BMI-35-or-higher route because 37 was the initiation BMI.¹

Read that again if you have been paying cash and losing weight.

You did not disqualify yourself by succeeding.

Two details matter:

• A cash purchase is not a Part D-paid fill. The current Bridge rule looks at whether a Medicare Part D plan paid for a GLP-1 fill in 2026. A cash purchase does not become a Part D claim just because you also have Medicare.¹
• A prior compounded start is still an open edge case. Public CMS guidance does not clearly say whether starting a compounded product establishes the initiation date for a later covered brand. Mark this [NEEDS VERIFICATION] and have the prescriber ask with your exact dates and records.

What we could not confirm: Public guidance does not clearly resolve every long treatment gap, restart, or switch from a compounded product to a covered brand. Do not guess. Your prescriber can call the Bridge prescriber line at 1-855-273-0102, Monday through Friday, 8 a.m. to 7 p.m. Eastern. Beneficiaries should call 1-800-MEDICARE for personal Medicare help.¹

Check 2: The BMI thresholds overlap

The Bridge thresholds are minimums, not three sealed-off boxes.

CMS says:

• BMI 35 or higher
• BMI 30 or higher with one of three listed conditions
• BMI 27 or higher with one of four listed conditions

Thirty-two is also 27 or higher. The official Medicare eligibility tool shows all seven listed conditions when the user selects BMI 30–34.9. The CMS prior-authorization form also lets a prescriber attest to the BMI-27 route for a person whose initiation BMI was above 27.¹

So a person whose initiation BMI was 32 and who had prediabetes can use the BMI-27-plus-prediabetes route, as long as the other Bridge requirements are met.

This is not a loophole. It is how the minimum thresholds are written.

Check 3: Look for more than one prediabetes test

Prediabetes is one of the Bridge conditions at an initiation BMI of 27 or higher. Do not search only for an A1C.

Standard diagnostic ranges include:²

Open your patient portal and search for:

• A1C
• hemoglobin A1c
• fasting glucose
• oral glucose tolerance test

Bring the result to your clinician. A lab number is not a self-diagnosis. The clinician must decide whether your record supports prediabetes and attest truthfully on the Bridge form.

One old result can still matter if it shows what was true when therapy began.

Check 4: “Uncontrolled high blood pressure” has a narrow Bridge definition

For the Bridge, uncontrolled hypertension means a systolic pressure above 140 or a diastolic pressure above 90 despite concurrent treatment with two blood-pressure medicines.¹

That means a reading of 150/95 while taking one medicine does not meet this specific Bridge definition. It does not mean the blood pressure is safe. It means the Bridge condition is narrower than the ordinary phrase “high blood pressure.”

Do not change medicines to fit paperwork. Ask whether your records at initiation already meet the rule.

Check 5: Confirm the plan and the correct coverage lane

The Bridge is for eligible people with Medicare Part D drug coverage. Current CMS guidance includes:

• Standalone Part D plans
• Medicare Advantage plans with drug coverage
• Special Needs Plans with drug coverage
• Employer or union group waiver drug plans
• LI NET
• Eligible people with both Medicare and Medicaid who are enrolled in a qualifying Part D plan¹

The plan type may not be the problem. The diagnosis may be sending the prescription to a different lane.

If the medicine is prescribed for type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH with moderate-to-advanced fibrosis, or another FDA-approved Part D-covered indication, the claim should generally be checked under the regular Part D benefit first.¹

Your 10-minute checklist

1. Find your BMI on the day you began GLP-1 therapy.
2. Find your earliest prescription date and the product you used.
3. Search for A1C, fasting glucose, and oral glucose tolerance results.
4. Check the number of blood-pressure medicines you were taking at initiation.
5. Confirm your Part D plan type and whether the diagnosis belongs in ordinary Part D.
6. Ask your prescriber to correct and resubmit if the wrong BMI or lane was used.

Run these checks before you compare a single cash price. If one comes back in your favor, the medicine may cost $50 through the Bridge instead of hundreds of dollars in cash.

Build my starting-BMI record list →

What BMI and Conditions Qualify for the Medicare GLP-1 Bridge?

The Bridge has three overlapping initiation-BMI routes: 35 or higher by itself, 30 or higher with one of three conditions, or 27 or higher with one of four conditions. The BMI and condition must describe the person when GLP-1 therapy began.

The other Bridge requirements

The person must also:

• Be enrolled in an eligible Medicare Part D plan
• Be prescribed a covered product for weight management with diet and physical activity
• Not have a Part D plan-paid GLP-1 fill in 2026
• Not be using the product under an ordinary Part D-covered indication that belongs in the Part D lane¹

Which products and forms does the Bridge cover?

Current CMS guidance covers:

• All Foundayo formulations
• All Wegovy formulations
• Zepbound KwikPen only

The Bridge does not cover Zepbound single-dose vials or single-dose pens. CMS also says pen needles are not covered under the Bridge, so ask the pharmacy what you need before pickup.¹

Use this order every time

1. Starting BMI
2. Bridge-listed condition at initiation
3. Part D-covered diagnosis
4. Product and formulation
5. 2026 Part D-paid fill history
6. Only then: cash price

Most pages start at number six. That is how people end up paying cash before anyone fixes the real problem.

FDA-Approved Use vs. Medicare Payment: What Is the Difference?

The FDA label and the Medicare Bridge answer different questions. The label describes the uses FDA has approved; the Bridge decides whether this temporary Medicare program will pay for a covered weight-management product. A person can miss the Bridge rules and still fall within an FDA-approved adult weight-management population.

The FDA label describes the uses FDA has approved. Licensed clinicians may sometimes prescribe an approved drug for an unapproved use, but FDA has not found that unapproved use safe and effective. This page does not route readers to off-label weight-loss prescribing simply because they can pay cash.³

The FDA-approved adult weight-management pattern

Current long-term prescription options commonly use this adult pattern:

• Obesity, commonly BMI 30 or higher; or
• Overweight, commonly BMI 27 or higher, plus at least one weight-related condition

The exact wording, contraindications, warnings, age limits, other indications, and dosing rules differ by product. The products below are not interchangeable.⁴

The Medicare Bridge line

The Bridge is narrower. It uses the initiation-BMI tiers and specific condition lists above. It also excludes people who should be using ordinary Part D for a covered indication and people with a Part D-paid GLP-1 fill in 2026.¹

The Medicare–FDA BMI Gap Matrix

We assembled this matrix from CMS criteria, FDA-approved adult weight-management populations, Part D routing rules, and current cash-access terms. Those facts usually live on separate pages.

The key difference is simple:

Your BMI can be too low for the Bridge price without being outside an FDA-approved adult weight-management population.

That is a coverage problem. It is not automatic proof that a medicine is right for you, and it is not a promise that a clinician will prescribe it.

Most People Who Met the Clinical Rules Still Failed Another Bridge Gate

KFF estimated that 9.7 million Part D enrollees met the Bridge’s clinical rules in 2023, but only 3.8 million met all the program criteria. The other 5.9 million had another gate, such as a Part D-covered diagnosis or a Part D-paid GLP-1 fill—not a failure to meet the BMI-and-condition test.⁵

KFF used 2023 Medicare claims and survey data to estimate the eligible population.

The 13.3 million figure covers Medicare Parts A and B, while the 3.8 million estimate covers Part D enrollees. They answer different questions and should not be divided into each other.

Why an exclusion can point to the correct coverage lane

A person prescribed a GLP-1 for type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH with moderate-to-advanced fibrosis, or another covered indication may belong under ordinary Part D instead of the Bridge.¹

That route can be better in three practical ways:

• Covered Part D spending counts toward the annual out-of-pocket limit. The limit is $2,100 in 2026 and $2,400 in 2027.⁶
• Extra Help can reduce ordinary Part D costs. Extra Help does not reduce the Bridge’s flat $50 copay.¹
• Part D has formal coverage-determination and appeal rights. The Bridge correction process is different and does not use the same formal appeal structure.¹

Do not read a Bridge exclusion as “Medicare will never cover me.” Ask which lane applies to the actual diagnosis and product.

Name the reason before choosing cash pay

A Bridge rejection should be labeled before anyone recommends cash pay:

This is how the page avoids treating every “no” as the same problem.

What Should You Say If Medicare Used the Wrong BMI?

You cannot submit the Bridge prior authorization yourself. Your prescriber can submit corrected, updated, or additional information when the wrong BMI, diagnosis, product, or route was used. The form asks the prescriber to attest to the facts; it does not ask the patient to upload a chart.¹

This is not a reason to give up. It is a focused correction.

How the Bridge request normally starts

1. The pharmacy submits the prescription to the Bridge.
2. The Bridge response says prior authorization is required.
3. The prescriber receives or starts the request.
4. The prescriber submits the initiation BMI and other required facts.
5. The Bridge generally makes the prior-authorization decision within 72 hours after receiving the request.¹

CMS says the pharmacy does not need to obtain a separate Part D denial before the Bridge request begins. The Bridge claim itself must still reach the point where prior authorization is requested.¹

Why the correction still needs records

The form does not require a chart upload, but that does not mean the number can be guessed. The prescriber signs an attestation. The safest path is to give the office the record that shows:

• Date GLP-1 therapy began
• Weight and height at initiation
• Calculated initiation BMI
• Product used at initiation
• Relevant diagnosis or lab result at initiation
• Pharmacy history when useful
• Current prescription and requested formulation

The message to send your prescriber

Copy this. Change the brackets. Send it through your patient portal.

My BMI today is lower because I have already been receiving GLP-1 therapy. CMS bases Medicare GLP-1 Bridge eligibility on BMI at initiation of GLP-1 therapy, not automatically on current BMI. My initiation BMI was [number] on [date]. At that time, I also had [Bridge-listed condition, if applicable].

Would you review the original record and submit corrected information using my initiation BMI and the correct coverage lane?

Please also check whether my records at initiation support prediabetes through A1C, fasting glucose, or an oral glucose tolerance test if that route applies.

What to bring with it

• The earliest office note that records your starting weight and height
• The date of your first GLP-1 prescription
• The medication and form you started
• Your A1C, fasting glucose, or oral glucose tolerance result
• Records of prior heart attack, stroke, symptomatic peripheral artery disease, HFpEF, qualifying hypertension treatment, or CKD stage 3a+ when relevant
• Pharmacy fill history if you paid cash
• Your current plan and pharmacy information

What not to say

Do not lead with:

• “I want to appeal.”
• “I know I qualify because a website said so.”
• “Can you change my weight?”

Lead with the initiation record and ask for a corrected submission.

If your own prescriber will not help

Some offices will not handle the Bridge. Some have not learned the initiation-BMI rule. Others may review the record and still decide that the clinical or program criteria are not met.

If the office simply will not handle the Medicare process, Sesame currently offers a Medicare-focused GLP-1 program. Sesame says its provider handles the Bridge paperwork and sends an eligible prescription to the pharmacy. Its current annual-plan price starts at $59 a month equivalent, while an approved Bridge product is billed separately at the $50 pharmacy copay. Some Sesame providers may charge more, and the annual commitment and current checkout terms matter.⁷

That produces a current $109 monthly equivalent for care plus the Bridge medicine when approved—not a guaranteed $109 all-in bill. Other visit, pharmacy, supply, tax, or plan-specific costs can still matter.

If your prescriber will not re-file, see Sesame’s current Medicare GLP-1 program →

You will see current plan terms, provider availability, and how the Medicare paperwork is handled. A prescription and Bridge approval are not guaranteed. Medication is billed separately.

And if your own prescriber will correct the request, use your own prescriber. You may not need another membership. We would rather tell you that than earn a commission on care you do not need.

Download the starting-BMI resubmission checklist →

Can You Get a Cash-Pay GLP-1 If BMI Is Too Low for Medicare Bridge?

Yes, a clinical cash-pay evaluation may still be possible when your starting BMI misses the Bridge rules but you fall within an FDA-approved adult weight-management population. Cash removes the Medicare payment rule; it does not remove the prescription requirement, medical review, warnings, or the clinician’s right to say no.

This is the question behind the whole search.

Four separate questions

Cash changes the fourth question. It does not erase the third.

The real cash-pay gap

The clearest gap is an adult whose initiation BMI was 30–34.9 without one of the Bridge-listed conditions. That person can miss the Bridge clinical tiers while still falling within the common FDA-approved adult obesity population.

A second gap is an initiation BMI of 27–29.9 with a weight-related condition recognized under the relevant product’s label but not included in the Bridge’s shorter condition list.

Those are the readers who may need a legitimate FDA-approved cash-pay evaluation after the Bridge and Part D paths are checked.

If your starting and current BMI are under 27

Paying cash does not create an FDA-approved weight-management use. A clinician can legally prescribe an approved drug off label in some circumstances, but FDA has not approved the product as safe and effective for that unapproved use.³

This page will not route a healthy-weight reader to a provider simply because the reader is willing to pay.

A provider that promises approval before reviewing your history is giving you useful information about the provider—not proof that the medicine fits you.

If body weight, food, or the number on the scale is becoming hard to control emotionally, use our product-free guide on GLP-1s and a history of disordered eating. That is a better next page than a checkout screen.

Do not trade a health outcome for a paperwork outcome

Do not intentionally regain weight to hit a threshold. Do not ask anyone to record an inaccurate weight. Do not stop appropriate treatment just to create a new “starting” number.

The paperwork is not worth it.

Four gates before a cash-pay referral

Before a cash-pay referral appears, the reader should pass all four gates:

1. The initiation-BMI correction was checked.
2. The ordinary Part D lane was checked.
3. The reader appears to fit an FDA-approved adult weight-management population or another approved indication.
4. A clinician still makes the final prescribing decision.

Only then does price become the next problem to solve.

Why Isn’t a Compounded GLP-1 a BMI Workaround?

A compounded GLP-1 is not an FDA-approved generic substitute and is not a way to erase medical eligibility. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed, and it says compounding should meet a patient need that an available approved drug cannot meet.⁸

That does not mean every compounded prescription is unlawful. It means the product and the claim must be described honestly.

What this page will not say

We will not describe a compounded product as:

• “Generic Wegovy”
• “Generic Zepbound”
• “The same as the brand”
• “The same active ingredient” as a blanket marketing claim
• “Clinically proven equivalent”
• FDA-approved

FDA has specifically warned companies about marketing unapproved GLP-1 products with generic, sameness, and unsupported efficacy claims.⁸

What cash compounding does not solve

It does not remove:

• The need for a prescription
• The clinician’s duty to evaluate the patient
• Product-quality questions
• State pharmacy and prescribing rules
• The difference between approved and unapproved products
• The need to verify the dispensing pharmacy

What remains unresolved for the Bridge

A compounded cash fill is not a Part D-paid fill. But public CMS guidance does not clearly say whether initiation on a compounded product establishes the Bridge initiation date for a later covered brand.

Mark that [NEEDS VERIFICATION]. Do not turn it into a sales claim.

This page compares FDA-approved products because the search is about Medicare, BMI eligibility, and the Bridge’s covered brands. Adding a compounded offer here would blur the very distinction the reader needs.

What Does a Cash-Pay GLP-1 Cost in 2026?

Current manufacturer-direct prices begin at $149 for the lowest doses of Foundayo and the Wegovy pill. The real range reaches $699 when a Zepbound higher-dose refill misses the current 45-day offer window. Every price below still requires a valid prescription, and manufacturer terms can change.

Here is what “from $149” leaves out: dose, form, offer deadline, care fees, refill timing, supplies, taxes, and whether a lower price is temporary.

Foundayo (orforglipron) — daily pill

Taxes and fees may apply. Current terms define a month as a 30-day supply.⁹

Missing the current refill window at the top doses changes the medication price by $50 for that fill.

Wegovy (semaglutide)

Eligibility and offer terms apply. Medication, dose, and form are clinical decisions.¹⁰

Zepbound (tirzepatide) — KwikPen

Lilly’s current terms define the KwikPen month as a 28-day supply. Pen needles may be a separate purchase.¹¹

Missing the current window at 10–15 mg changes the medication price by $250 for that fill. Set a reminder before day 45 if a clinician prescribes one of those doses and the offer still exists.

Two Medicare details people confuse

Commercial savings cards are not the same as self-pay prices. Manufacturer copay cards commonly exclude Medicare, Medicaid, and other government coverage. The cash prices above are separate manufacturer-direct programs with their own terms.⁹¹⁰¹¹

A cash purchase stays outside the Medicare drug benefit. Do not submit it for Medicare reimbursement or assume it counts toward the Part D deductible or out-of-pocket limit. Medicare also says TrumpRx is a price-comparison path, not a pharmacy, and purchases made outside Part D do not count toward Medicare drug spending totals.¹²

Manufacturer-direct links

• See current Foundayo self-pay terms
• See current Wegovy self-pay terms
• See current Zepbound KwikPen self-pay terms

We do not earn a commission from those manufacturer-direct links.

Your result separates the medication from the care fee, shows any prepaid commitment, and calculates first-, six-, and twelve-month totals. It does not predict or recommend a dose.

Your Own Doctor, Sesame, or Ro: Which Route Costs Less?

Your existing prescriber plus a manufacturer-direct pharmacy usually has the lowest added care cost. Sesame is the stronger fit when the problem is getting a clinician to handle the Bridge. Ro is the primary cash-pay affiliate route when the reader needs an integrated FDA-approved telehealth program and accepts an added membership fee.

The cheapest route and the easiest route are not always the same.

Provider-stated vs. source-verified comparison

Sesame and Ro do not guarantee that a clinician will prescribe a medicine. The clinician decides after evaluation.⁷¹³

The all-in monthly comparison at a $349 Wegovy injection price

This is an example, not a prediction of what product or dose a clinician will choose.

The honest downside: Ro costs more than buying direct

Ro does not beat the manufacturer’s medication price. If you already have a clinician who will prescribe and manage treatment, Ro’s care fee is an added $74 to $149 monthly equivalent that you may not need.

If that is your situation, skip the affiliate route and buy through the manufacturer-direct pharmacy after your clinician prescribes. We make nothing when you do that.

But Ro is not selling a cheaper drug. It is selling the care layer that many readers are missing. Current Ro terms include clinical evaluation, secure messaging, prescription management, refills, and insurance support. The first month is $39, and Ro says that charge is refunded when its clinician finds the person ineligible for GLP-1 treatment.¹³

Know the limits before you click:

• Medicine is billed separately.
• The $74 monthly equivalent requires an annual plan paid upfront.
• The month-to-month care fee is $149 after the first month.
• The plan auto-renews under the current terms.
• Cancellation must be completed before the renewal deadline stated in the terms.
• Secure messaging is not emergency care and is not the same as 24/7 live clinician access.
• A prescription is never guaranteed.
• Medicare and Medicaid are not billed; a government-benefit enrollee using Ro pays outside the benefit and agrees not to seek reimbursement or count the spending toward Medicare out-of-pocket totals.¹³

The honest downside: Sesame’s lowest price comes with a commitment

Sesame’s current price starts at a $59 monthly equivalent and is tied to an annual plan; some providers may charge more. Medicine is separate, and approval for the $50 Bridge fill is separate. Current terms also describe renewal, cancellation timing, and pricing consequences for ending a discounted multi-month commitment early.⁷

Sesame makes the most sense when the missing piece is a clinician who will handle the Medicare process—not when an existing prescriber will already do it.

What real customers say about the service experience

These short quotes are about process and communication. They are not evidence that a medicine works, that a person will lose weight, or that treatment is safe for a particular reader.

“Process was quick and easy.”
— C. Phillipson, Trustpilot review of Ro, invited review; visible August 5, 2026¹⁴

“Communication from both the website and from my doctor are excellent.”
— David Gilbertson, Trustpilot review of Sesame, unprompted, August 3, 2026¹⁴

Review pages can change. Re-open and screenshot each source before publishing, and remove a quote if it can no longer be verified.

If you have confirmed that you are truly outside the Bridge

You ran the starting-BMI checks. You checked ordinary Part D. Your initiation BMI does not qualify for the Bridge. You do not already have a prescriber willing to manage an FDA-approved cash-pay option.

That is the reader Ro can fit.

Does that sound like your situation? Check clinical eligibility and current FDA-approved cash pricing with Ro →

You will see current care fees, available medicines, state availability, and the clinical intake. The $39 first-month care charge is currently refundable if Ro finds you ineligible for GLP-1 treatment. Medication is separate.

Are There Cheaper Non-GLP-1 Weight-Loss Medicines?

Yes. Older FDA-approved weight-management medicines can cost less than a GLP-1, but they are different drugs with different benefits, warnings, contraindications, and expected results. They are alternatives to discuss with a clinician—not cheap versions of Wegovy, Zepbound, or Foundayo.

Weight-loss percentages from separate trials are not a clean head-to-head comparison. A safer comparison here is the current official cash-access price and the practical tradeoff.

Official program prices and eligibility terms can change.¹⁵

The honest trade

A lower monthly price does not make an older medicine the right medicine. A clinician must compare:

• Your health history
• Current medicines
• Blood pressure
• Seizure history
• Opioid use
• Pregnancy potential
• Kidney or liver issues
• Side-effect tolerance
• The amount of follow-up you need

If price is the thing stopping you, ask this before committing to a long cash-pay GLP-1 plan:

“Is there a lower-cost FDA-approved weight-management medicine that fits my health history, and what would I give up or take on by choosing it?”

The BMI and clinical evaluation still matter. A lower price is not a route around appropriate prescribing.

What Free or Low-Cost Help Can Medicare Already Give You?

Before paying full price, check Medicare-covered obesity counseling, free SHIP counseling, State Pharmaceutical Assistance Programs, and Medicare’s patient-assistance lookup tools. None guarantees that a GLP-1 will be covered, but each can solve a different part of the cost problem.

Medicare-covered obesity behavioral therapy

Medicare Part B covers intensive behavioral therapy for obesity when the person has a BMI of 30 or higher and the service is delivered in an eligible primary-care setting. When the provider accepts assignment and the coverage rules are met, the patient pays nothing for the covered service.¹⁶

That benefit is separate from the Bridge.

A person with a BMI of 32 who misses the Bridge’s clinical tiers may still qualify for covered obesity counseling. Ask the primary-care office whether it provides the service under the Medicare benefit.

Free SHIP counseling

Every state has a State Health Insurance Assistance Program. SHIP counselors give free, local Medicare help and do not sell plans.¹⁷

A SHIP counselor can help you:

• Identify your Part D plan type
• Understand plan notices
• Find the plan’s prior-authorization process
• Locate state drug-assistance programs
• Compare coverage choices without an affiliate sale

Find your local SHIP counselor →

State Pharmaceutical Assistance Programs

Some states operate programs that help eligible residents with prescription-drug costs. Rules vary by state, income, diagnosis, age, and product.

Use Medicare’s official state-program lookup rather than assuming your state has one.¹⁷

Patient-assistance program lookup

Medicare also maintains tools for finding manufacturer patient-assistance programs. These are different from commercial copay cards, and each program has its own eligibility rules.¹⁷

Do not publish a blanket promise that a particular Medicare beneficiary will receive a free or discounted GLP-1. Check the exact program and current product terms.

What these programs cannot do

They do not:

• Change the Bridge initiation-BMI rule
• Guarantee Part D coverage
• Guarantee that a clinician will prescribe
• Turn a commercial coupon into a Medicare benefit
• Make cash spending count toward Part D out-of-pocket totals

They can still save a reader from paying for help that already exists.

Which free resource solves which problem?

Each resource fixes a different problem. Calling all of them “discount help” sends people to the wrong place.

What Happens When These Prices or the Bridge End?

The Medicare GLP-1 Bridge is currently scheduled to run through December 31, 2027. Several manufacturer cash offers end sooner, so the page must be rechecked by date—not merely relabeled with a new year.

CMS says the Bridge was extended through the end of 2027 after the BALANCE model did not launch in 2027. That is the current fact. Do not promise that BALANCE will begin on a certain date, that Congress will fund a replacement, or that the Bridge will definitely continue.¹

Do not generalize missed-dose instructions

Missed-dose and restart instructions differ by medicine, dose, and time away. A single “two-week” rule does not apply to every product.

If treatment is interrupted, contact the prescriber before restarting or changing the dose. Do not use a general web article as a dosing instruction.

How we keep this page current

Last verified: August 5, 2026. We recheck CMS criteria, covered forms, manufacturer cash prices, provider fees, and offer deadlines monthly. The date changes only after those facts are reverified.

We keep an internal log of the fact checked, the old and new value, the exact source, the date, and the section changed. A stale “last updated” date is worse than no date at all.

What We Actually Verified—and What We Couldn’t

We checked the government rule, the official eligibility tool, the Bridge form, current FDA labels, manufacturer cash terms, provider pricing and terms, and KFF’s eligibility analysis. We separated facts from editorial judgments and left unresolved edge cases marked instead of guessing.

What we checked on August 5, 2026

• The Medicare GLP-1 Bridge dates, $50 copay, plan types, clinical tiers, initiation-BMI rule, covered products, Part D routing, and correction process
• The official Medicare eligibility tool’s treatment of overlapping BMI thresholds
• The official Bridge prior-authorization form and prescriber attestation
• Current FDA-approved adult weight-management uses and the difference between approved and off-label use
• Current Foundayo, Wegovy, and Zepbound manufacturer-direct cash prices by dose
• Current offer deadlines and Zepbound refill-window prices
• Current Ro care prices and cash-pay terms
• Current Sesame Medicare-program price and plan structure
• KFF’s 2023 population estimate
• Medicare’s 2026 and 2027 Part D out-of-pocket limits
• Current Qsymia and Contrave cash-access program prices
• Medicare obesity-counseling and SHIP resources

What we could not confirm

1. How every long treatment gap or restart affects the Bridge initiation date.
2. Whether initiation on a compounded product establishes the initiation date for a later covered brand.
3. Whether an individual reader meets the clinical criteria. Only the treating clinician can decide that.
4. Whether an individual Part D plan will cover a particular prescription. The plan and prescriber must complete that process.
5. Whether Ro, Sesame, or another provider serves a particular state at the moment the reader applies. Check the live intake.
6. Whether the two customer-review quotes will remain visible. Re-open and archive them before publication.

Facts vs. our conclusions

Fact: CMS uses BMI at initiation of GLP-1 therapy for Bridge eligibility.
Our conclusion: Check the starting-BMI record before comparing cash prices.

Fact: The official Medicare tool treats the BMI thresholds as overlapping minimums.
Our conclusion: A person at BMI 32 with prediabetes should not be rejected merely because a form was read as three exclusive bands.

Fact: Manufacturer-direct medication prices can match the medication price available through a telehealth platform.
Our conclusion: An existing prescriber plus manufacturer direct is usually the lowest-overhead cash route.

Fact: Ro adds a care fee, while Sesame’s lowest current care price uses an annual plan.
Our conclusion: Ro fits integrated cash-pay care; Sesame fits Bridge help; neither should replace a willing existing prescriber without a reason.

How this page was made

Weight Loss Provider Guide created this page by comparing sources that readers normally have to open one by one:

• CMS program rules
• The Medicare eligibility tool
• The actual Bridge form
• FDA labels and FDA off-label guidance
• Manufacturer-direct price terms
• Provider pricing and membership terms
• KFF population estimates

We then assembled three original decision assets:

1. The Medicare–FDA BMI Gap Matrix
2. The dose-and-refill cash-price ladder
3. The care-fee-plus-medication cost comparison

This page exists to answer one question: when BMI is the known problem, should the reader correct the Medicare submission, use ordinary Part D, seek an FDA-approved cash-pay evaluation, or stop commercial routing?

Weight Loss Provider Guide is not a medical practice. This page is not medical advice. A licensed clinician decides whether a medicine is appropriate.

Frequently Asked Questions

Can Medicare use my starting BMI if my BMI is lower now?

Yes. The Bridge uses your BMI at initiation of GLP-1 therapy. CMS gives an example of a person who began at BMI 37 and later reached 34; the prescriber should use the initiation-BMI route that applied at 37. Give the office the original date, weight, height, and record.¹

What BMI do you need for the Medicare GLP-1 Bridge?

The initiation-BMI routes are 35 or higher by itself; 30 or higher with HFpEF, qualifying uncontrolled hypertension, or CKD stage 3a+; or 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease. The thresholds overlap.¹

My BMI was 32 and I had prediabetes. Can I use the BMI-27 route?

Yes, if the other Bridge requirements are met. Thirty-two is 27 or higher, and the official Medicare tool shows prediabetes as an available condition for the 30–34.9 group. The prescriber still must submit accurate initiation information.¹

Can I get Wegovy if my BMI is 30?

An adult with obesity may fall within Wegovy’s FDA-approved weight-management population even without one of the Bridge’s narrow listed conditions. That does not guarantee a prescription. A clinician must review the individual’s history, warnings, contraindications, and treatment plan.⁴

Does paying cash get around the BMI requirement?

No. Cash removes the insurance payment decision. It does not remove clinical evaluation, prescription requirements, product warnings, or the clinician’s ability to decline treatment.

How much is Wegovy without insurance if I have Medicare?

Current manufacturer-direct pricing is $149 for the 1.5 mg pill, $149 for the 4 mg pill through August 31, 2026, $299 for the 9 mg and 25 mg pills, $349 for the standard injection dose range, and $399 for the 7.2 mg HD injection. Eligible new patients can currently receive the first 0.25 mg and 0.5 mg injection fills for $199 each through December 31, 2026. Terms apply.¹⁰

Can Medicare beneficiaries use the Foundayo, Wegovy, or Zepbound cash prices?

The manufacturer self-pay programs are separate from commercial copay cards. The cash transaction stays outside Medicare under the current terms. Do not submit it for Medicare reimbursement or count it toward Part D out-of-pocket spending.^9101112

Does cash-paid compounded semaglutide disqualify me from the Bridge?

A cash purchase is not a Part D-paid fill. But CMS public guidance does not clearly say whether starting a compounded product establishes the initiation date for a later covered brand. That part is [NEEDS VERIFICATION] and should be checked by the prescriber with exact dates and records.

Can I appeal a Bridge denial?

The Bridge does not use the same formal appeal process as ordinary Part D. CMS says a prescriber can submit corrected, updated, or additional information. For a wrong-BMI problem, ask for a corrected submission using the initiation record.¹

Does the $50 Bridge copay count toward my Medicare Part D out-of-pocket limit?

No. Bridge spending is outside the Part D benefit. It does not count toward the Part D deductible or annual out-of-pocket limit, and Extra Help does not reduce the $50 Bridge copay.¹

What is the Medicare Part D out-of-pocket limit?

The annual limit is $2,100 in 2026 and $2,400 in 2027. Covered Part D spending can count toward those limits; Bridge and outside-benefit cash spending do not.⁶

Is Zepbound $449 for every higher-dose cash fill?

Only when the current offer terms are met. The advertised price for 7.5–15 mg is $449 when the KwikPen is purchased within 45 days of the prior fill. The current regular price is $499 at 7.5 mg and $699 at 10–15 mg when that window is missed.¹¹

Are Zepbound KwikPen needles included?

Do not assume they are. CMS says the Bridge covers Zepbound KwikPen but not pen needles. Ask the pharmacy what needles are needed and what they cost before pickup.¹

Can people with both Medicare and Medicaid use the Bridge?

Some can. CMS includes eligible people with both Medicare and Medicaid when they are enrolled in a qualifying Part D plan and meet the other Bridge rules. The result depends on the person’s plan and clinical facts.¹

Can a person with Medicare use Ro as a cash-pay service?

Current Ro terms provide a cash-pay route outside Medicare and Medicaid. Ro does not bill those programs, and the enrollee agrees not to seek government reimbursement or count the spending toward Medicare out-of-pocket totals. Clinical eligibility, state availability, care fees, and medication costs still apply.¹³

What is the cheapest FDA-approved cash-pay option on this page?

Among the current products priced here, Foundayo 0.8 mg and Wegovy pill 1.5 mg begin at $149. That is a starting-dose price, not a promise of the dose a clinician will choose or the price a reader will pay later.⁹¹⁰

Is there a cheaper weight-loss medicine than a GLP-1?

Yes. Current official cash-access examples include Qsymia at $89 for 30 days or $210 for 90 days where offered, and Contrave at $99 a month through its current cash program. They are different medicines with different warnings and are not GLP-1 substitutes.¹⁵

What if my starting and current BMI are 26?

You are outside the usual FDA-approved adult weight-management population based on BMI alone. Paying cash does not create an approved use. Off-label prescribing can occur in medical practice, but this page does not route readers to it; ask a clinician what care is appropriate.³⁴

What happens if I stop and restart?

Do not use one rule for every GLP-1. Restart instructions differ by medicine, dose, and time away. Contact the prescriber before restarting or changing a dose. The Bridge treatment of some long-gap restarts is also [NEEDS VERIFICATION].

When does the Medicare GLP-1 Bridge end?

The current end date is December 31, 2027. Check CMS before relying on any page that still says December 31, 2026.¹

Still Not Sure Which GLP-1 Program Is Right for You?

Your current BMI is only one piece of the answer. Your starting BMI, Part D route, existing prescriber, preferred form, health history, and sustainable monthly budget all change the right next step.

Take our free 60-second matching quiz and get a personalized action plan—including whether you should correct the Bridge submission instead of paying cash.

Take the free 60-second matching quiz →

Last verified: August 5, 2026. Prices, program rules, provider terms, and eligibility criteria change. We recheck the CMS criteria, covered products, manufacturer cash prices, and provider fees monthly. We update the date only after those facts are reverified.

Sources